Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer

[1] Davies C(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[2] Godwin J(2005)Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen Clin Cancer Res 11 5671-5677

[3] Gray R(2007)Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a J Natl Cancer Inst 99 1845-1853

[4] Clarke M(2008)Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial J Clin Oncol 26 1965-1971

[5] Cutter D(2005)Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer Lancet 365 60-62

[6] Darby S(2003)A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793-1802

[7] Mann BS(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1092

[8] Johnson JR(2012)Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis Oncologist 17 55-63

[9] Kelly R(2006)Adherence to tamoxifen over the five-year course Breast Cancer Res Treat 99 215-220

[10] Sridhara R(2008)Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 99 1763-1768

[1] Davies C(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[2] Godwin J(2005)Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen Clin Cancer Res 11 5671-5677

[3] Gray R(2007)Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a J Natl Cancer Inst 99 1845-1853

[4] Clarke M(2008)Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial J Clin Oncol 26 1965-1971

[5] Cutter D(2005)Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer Lancet 365 60-62

[6] Darby S(2003)A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793-1802

[7] Mann BS(2004)A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081-1092

[8] Johnson JR(2012)Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis Oncologist 17 55-63

[9] Kelly R(2006)Adherence to tamoxifen over the five-year course Breast Cancer Res Treat 99 215-220

[10] Sridhara R(2008)Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 99 1763-1768